相关实验视频

Updated: Sep 9, 2025

A Preclinical Murine Model of Hepatic Metastases

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

DHCR7通过PI3K-Akt信号通路促进胰腺癌的肝转移

Yu Xie¹, Ziyue Zhou^1,2, Jiangwei Song^1,2

¹Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

|September 2, 2025

概括

胰腺癌的肝转移情况尚不清楚. 我们的研究发现7-脱胆固醇减少酶 (DHCR7) 是促进癌症扩散的关键驱动因素,

科学领域:

癌症学
分子生物学
生物化学

背景情况:

胰腺癌 (PC) 结果不佳,通常是由于肝脏转移 (LM).
PC肝转移的分子驱动因素和治疗点是有限的.
了解PC转移机制对于改善患者的生存至关重要.

研究的目的:

确定导致胰腺癌转移的分子机制.
研究7-脱胆固醇减少酶 (DHCR7) 在PC进展中的作用.
评估DHCR7作为PC肝转移的潜在生物标志物或治疗标.

主要方法:

在PC组织中分析DHCR7表达和与LM的相关性.
在体外研究评估DHCR7对PC细胞增殖,入侵和迁移的影响.
在体内实验以确定DHCR7在促进PC肝转移中的作用.
研究DHCR7,胆固醇合成和PI3K-Akt路径之间的机制联系.

主要成果:

DHCR7在PC组织中显著上调,与LM相关.
在体外,DHCR7的过度表达增强了PC细胞的增殖,侵入和迁移.
在体内,DHCR7促进肝脏PC转移.
DHCR7提高胆固醇的合成,并激活PC细胞中的PI3K-Akt通路.

结论:

DHCR7是胰腺癌中肝转移的一个新型分子驱动因素.
通过胆固醇合成和PI3K-Akt激活,DHCR7的上调促进了PC的进展.
DHCR7是胰腺癌肝转移的潜在预测生物标志物和治疗点.

关键词:

7-脱水胆固醇减少酶根据该法案,胆固醇的代谢肝脏转移胰腺癌

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...